India, April 21 -- Daiichi Sankyo Co., Ltd. (DSKYF.PK) announced Monday that Enhertu (trastuzumab deruxtecan), co-developed and commercialized with British drug major AstraZeneca Plc. (AZN.L,AZN), Plus Pertuzumab showed positive topline results in a phase 3 trial in breast cancer patients.
The results from a planned interim analysis of the DESTINY-Breast09 phase 3 trial showed that Enhertu in combination with pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival or PFS compared to taxane, trastuzumab and pertuzumab (THP) as a first-line treatment for patients with HER2 positive metastatic breast cancer.
HER2 positive metastatic breast cancer is an aggressive disease d...